Top News in R&D
 
 

 

 

READ ONLINE

 

 
 
 
 Global Health Technologies Coalition 
 
 
 
 

 

R&D News Roundup: January 8, 2023

 

Top News in R&D

New antibiotic compound very exciting, expert says
BBC (1/4), features GARDP

Newly published research from the Global Antibiotic Research and Development Partnership (GARDP) found that a new compound worked in test tubes and mice against infections caused by the carbapenem-resistant Acinetobacter baumannii (CRAB) bacterium. CRAB can cause serious infections and death in critically ill hospital patients, is classed as a priority pathogen by the World Health Organization, and is resistant to many known antibiotics. The drug, zosurabalpin, was identified after screening about 45,000 small molecules with potential antibiotic properties and seems to be effective against the bacterium’s notoriously tricky structure. While research is still in early stages, the results provide hope for the potential treatment of hard-to-treat infections caused by CRAB and other bacteria.

Scientists discover the first new antibiotics in over 60 years using AI
EuroNews (12/31)

A research team used artificial intelligence (AI) to discover a new class of antibiotics for methicillin-resistant Staphylococcus aureus bacteria, better known as MRSA, which kills thousands globally every year. The researchers used deep-learning models to screen approximately 12 million commercially available compounds and then conducted lab tests for around 280 of them, eventually identifying and testing in mice two promising antibiotic candidates from the same class. The research not only points to a potential treatment for MRSA but also highlights the potential of AI in speeding up drug discovery.

Newly-identified flu antibodies could form the basis of better vaccines
Fierce Biotech (12/22)

A recent study provided insight into newly identified flu-fighting antibodies that could lead to the development of broader, more durable flu vaccines. The researchers examined the curiously strong immune responses in certain individuals after they received a trivalent flu vaccine and discovered the production in some people of a specific type of antibody that targets two dominant flu strains. By reverse-engineering their immune responses, researchers hope to improve our understanding of how to produce a vaccine that could elicit antibodies against multiple strains of the flu. While this research does not take us closer to developing a truly universal flu vaccine, these insights could lead to improved vaccines that offer better, longer-lasting protection against multiple flu subtypes.

 

 

News from GHTC

CEPI partners with Lemonex to advance mRNA vaccine delivery against future pandemic threats
Coalition for Epidemic Preparedness Innovations (CEPI) press release (1/4)

Treatment for acute sleeping sickness has been brutal—until now
NPR (1/2), features the Drugs for Neglected Diseases initiative

Could an HIV cure be based on the same breakthrough as the new treatment for sickle cell?
The Body (12/26), features Treatment Action Group and the Bill & Melinda Gates Foundation

Barinthus' new mission gets $35M booster from CEPI funding to develop MERS shot
Fierce Biotech (12/21), features CEPI

 

 

Highlights From the Week

 

 

COVID-19 R&D Roundup

 

 

Upcoming Events